What the FDA labels say about taking them together

Ranibizumab and verteporfin

Ranibizumab's FDA label of November 21, 2025 names verteporfin in its warnings and precautions section; the verteporfin label PlainMeds reads does not name ranibizumab.

Check it at the source: the ranibizumab FDA label on DailyMed (effective November 21, 2025, Genentech, Inc.); the verteporfin FDA label on DailyMed (effective August 27, 2025, Bausch Health US LLC).

What does the ranibizumab label say about verteporfin?

Ranibizumab label, warnings and precautions
In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg LUCENTIS compared to 1.1% (5 of 435) in patients in the control arms [odds ratio 2.2 (95% confidence interval (0.8-7.1)].

Source: FDA drug label (Nufymco, BLA761473), Zydus Pharmaceuticals USA Inc., effective June 4, 2026 (SPL set 05ed75bc-ae21-480b-9be4-cbc51689dd8a), via openFDA

Source: FDA drug label (LUCENTIS), Genentech, Inc., effective November 21, 2025 (SPL set de4e66cc-ca05-4dc9-8262-e00e9b41c36d), via openFDA; the full label on DailyMed

What does the verteporfin label say about ranibizumab?

Verteporfin's label (effective August 27, 2025) does not name ranibizumab in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Visudyne), Bausch Health US LLC, effective August 27, 2025 (SPL set 952f4c80-50b1-4308-9ee6-311ffefb13df), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Ranibizumab generic labelers

0Verteporfin generic labelers

	Ranibizumab	Verteporfin
Labeled for	n/a	n/a
Boxed warning	No	No
Pharmacy cost (NADAC)	n/a	n/a
Shortage now	No current entry	No current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Ranibizumab: the full record
Verteporfin: the full record
Check more medicines together: up to five at once